Published On : September 2026
A buyer treating engagement model as a simple contract-length decision is skipping the distinction that actually determines whether a DEL screening program can even be delivered as planned: regulatory and quality environment.
Within the cellular DNA-encoded library screening market, engagement model, fee-for-service screening, discovery partnership programs, co-development agreements, licensing arrangements or platform access models, is a structural choice tied to which regulatory and quality environment a program operates under, not merely a contract term negotiated independently of it.
This page describes five engagement model categories and four regulatory and quality environment categories strictly as market segments.
It provides no pricing figures, milestone payment structures, licensing economics or contract value figures, and makes no claim about the screening performance or hit-validation success rate of any named provider.
A program that must run under a GLP-compliant designation generally cannot simply select any engagement model without first confirming the provider can actually deliver work at that quality standard.
That is why business development and procurement teams experienced in this market confirm regulatory and quality environment alignment before finalizing engagement model terms.
Four regulatory and quality environment categories complete the specification once engagement model is settled, spanning GLP-compliant discovery programs, non-GLP research programs, preclinical development programs and translational research programs.
For buyers, establishing which regulatory and quality environment a program requires is the starting point for narrowing which providers and engagement models are actually viable.
For providers, offering multiple engagement models across both GLP-compliant and non-GLP environments widens the addressable share of any discovery partner's procurement requirements.
Regulatory and quality environment misalignment discovered late in a partnership is one of the more disruptive issues a discovery program can encounter, since shifting from a non-GLP to a GLP-compliant environment midstream can require requalifying work already completed.
Decision-maker roles also vary by engagement model, with a chief scientific officer more directly involved in evaluating a deep co-development agreement than a shorter fee-for-service screening round, which a discovery program leader can often approve with less senior involvement.
Fee-for-service screening and discovery partnership programs form two of the five engagement model categories tracked in this report, representing opposite ends of the commitment spectrum a buyer can choose.
Fee-for-service screening generally suits a buyer with a narrower, well-defined screening need, typically involving exploratory evaluation and a single scientific assessment round rather than an ongoing relationship.
Discovery partnership programs generally suit a buyer seeking a longer, multi-year relationship, typically progressing through pilot validation before contract negotiation on a broader, program-based agreement.
Both engagement models remain available across the GLP-compliant and non-GLP research program categories tracked in this report, though discovery partnership programs more frequently operate under a GLP-compliant designation once a program has progressed toward regulatory-facing work.
A buyer starting with fee-for-service screening retains the option to expand into a discovery partnership program later, an incremental approach several emerging biotech companies favor over committing to a multi-year relationship before a provider relationship has been tested.
|
PROCUREMENT INSIGHT Buyers moving from a single fee-for-service screening round into a full discovery partnership program generally benefit from confirming upfront whether the provider's regulatory and quality environment can scale with the relationship, since a mismatch discovered only after a partnership is signed is harder to resolve than one caught during pilot validation. |
Co-development agreements, licensing arrangements and platform access models complete the engagement model dimension tracked in this report, generally representing the deepest and longest-term buyer commitments among the five categories.
Co-development agreements generally involve shared scientific direction between buyer and provider, distinct from the more provider-led structure typical of fee-for-service screening or a straightforward licensing arrangement.
Licensing arrangements generally center on access to a specific chemistry platform or library rather than an ongoing collaborative screening relationship, appealing to buyers who want defined access rights without a broader partnership structure.
Platform access models generally suit buyers who want ongoing internal access to a provider's screening technology and chemistry platforms across multiple programs, rather than a single-project or single-library arrangement.
The provider types offering each engagement model differ meaningfully, and this report's supplier landscape by provider type explains which specialist, in-house pharma and CRO provider types most commonly offer platform access models versus narrower licensing arrangements.
Budget ownership for these deeper engagement models more frequently sits with R&D leadership or business development groups than with a single therapeutic area head, reflecting the cross-program scope that co-development agreements and platform access models typically carry.
External innovation teams, a decision-maker role distinct from a program's core scientific staff, are frequently the first point of contact for a co-development agreement or platform access model, reflecting these engagement models' strategic rather than purely operational character.
GLP-compliant discovery programs and non-GLP research programs form two of the four regulatory and quality environment categories tracked in this report, each named here strictly as a market category with no claim made about what a GLP designation actually certifies scientifically.
GLP-compliant discovery programs generally follow a more formal quality and documentation standard than non-GLP research programs, a distinction buyers typically confirm before selecting an engagement model that will scale toward later, more regulatory-facing discovery stages.
Non-GLP research programs generally suit earlier, more exploratory discovery stage work such as target identification and hit discovery, where formal GLP documentation is not yet required.
Buyers moving a program from an earlier discovery stage toward candidate selection frequently need to transition from a non-GLP to a GLP-compliant environment, a shift that can itself influence which engagement model and provider remain suitable.
Providers able to demonstrate a track record across both GLP-compliant and non-GLP environments generally have an advantage when a discovery partner's program requirements shift over the life of an engagement.
Preclinical development programs and translational research programs complete the regulatory and quality environment dimension tracked in this report, both generally sitting later in a discovery program's overall lifecycle than the GLP-compliant and non-GLP distinction alone captures.
Preclinical development programs generally follow candidate selection, once a program has moved beyond DEL screening's core hit-identification role into the broader preclinical development process.
Translational research programs generally bridge early discovery-stage work and later preclinical development, a category particularly relevant to translational medicine centers among this report's end user categories.
For buyers, recognizing which regulatory and quality environment category a program currently sits in, and which it will need to move toward, is a useful input into engagement model selection well before contract negotiation begins.
Translational research programs in particular frequently involve academic or government research organization partners alongside an industry buyer, reflecting the collaborative, cross-institutional character this regulatory and quality environment category often carries.
Sales cycle length for programs operating under a translational research designation is generally longer than for an early, exploratory non-GLP program, reflecting the additional institutional coordination that translational partnerships typically require.
Buyers evaluating a DEL screening partner generally weigh vendor selection criteria including library diversity, cellular screening capability, hit validation success rates, scientific expertise, partnership flexibility and data quality.
The screening technologies available under each engagement model is a further evaluation criterion, and this report's cellular DEL screening technology and chemistry platform breakdown sets out which screening technologies and chemistry platforms a given provider typically offers under fee-for-service, partnership or platform access arrangements.
Sales cycle length across this market generally runs from exploratory evaluation through scientific assessment, pilot validation and contract negotiation before reaching a multi-year engagement, a sequence that applies broadly regardless of which engagement model a buyer ultimately selects.
Decision-maker roles typically involved in this evaluation include chief scientific officers, heads of drug discovery, VP translational research, VP biology, discovery program leaders and external innovation teams, with budget ownership generally resting with R&D leadership, therapeutic area heads, platform technology teams or business development groups.
Contract negotiation timelines generally lengthen when a buyer is evaluating multiple engagement models simultaneously across more than one provider, since aligning regulatory and quality environment requirements, engagement model preference and screening technology fit across several candidates takes longer than a single-provider evaluation.
Partnership flexibility, one of the vendor selection criteria this market tracks, becomes particularly important when a buyer expects its regulatory and quality environment requirements to change over the life of an engagement, since a provider unable to flex between GLP-compliant and non-GLP work can become a bottleneck later in the relationship.
Buyers can access DEL screening through fee-for-service screening, discovery partnership programs, co-development agreements, licensing arrangements or platform access models.
GLP-compliant discovery programs generally follow a more formal quality and documentation standard than non-GLP research programs, which more commonly suit earlier, exploratory discovery stage work such as target identification and hit discovery.
Buyers generally weigh vendor selection criteria including library diversity, cellular screening capability, hit validation success rates, scientific expertise, partnership flexibility and data quality, alongside which screening technologies and chemistry platforms a provider offers under a given engagement model.
A platform access model generally gives a buyer ongoing internal access to a provider's screening technology and chemistry platforms across multiple programs, distinct from a single-project fee-for-service engagement or a narrower licensing arrangement.
Sales cycles in this market generally run through exploratory evaluation, scientific assessment, pilot validation and contract negotiation before reaching a multi-year engagement, a sequence that applies broadly regardless of engagement model.